Showing results (1-10 of 16) with videos related to

Sort By:
Pageof 2
Vascular Health and Risk Management|February 27, 2007
Ximelagatran: direct thrombin inhibitorShir-Jing Ho, Tim A Brighton
Hematology (Amsterdam, Netherlands)|June 7, 2008
Platelet function testing in uraemic patientsShir-Jing Ho, Rosalie Gemmell, Timothy A Brighton
Thrombosis Research|July 30, 2023
A retrospective validation of ROTEM algorithms for detecting hyperfibrinolysis demonstrates poor agreement for prediction of in-hospital mortality and transfusion requirement in a general, non-cardiac, surgical populationLeon Rosebery, Matthew Miller, Peter Loizou, et al.
Canadian Journal of Kidney Health and Disease|June 12, 2020
Crystalglobulinemia in Multiple Myeloma: A Rare Case Report of Survival and Renal RecoveryAngela Chou, Christopher Long, Leon Vonthethoff, et al.
Blood|May 15, 2015
A novel triple therapy for ITP using high-dose dexamethasone, low-dose rituximab, and cyclosporine (TT4)Philip Young-Ill Choi, Fernando Roncolato, Xavier Badoux, et al.
Leukemia & Lymphoma|June 9, 2016
Results of a phase II study of thalidomide and azacitidine in patients with clinically advanced myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and low blast count acute myeloid leukemia (AML)Melita Kenealy, Nigel Patton, Robin Filshie, et al.
European Journal of Clinical Pharmacology|October 7, 2022
Challenges associated with test dose pharmacokinetic predictions of high dose melphalan exposure in patients with multiple myelomaChrista Ellen Nath, Andrew Grigg, Sebastian P A Rosser, et al.
Blood Advances|March 22, 2023
Molecular associations of response to the new-generation BTK inhibitor zanubrutinib in marginal zone lymphomaMaciej Tatarczuch, Mark Waltham, Jake Shortt, et al.
British Journal of Haematology|July 18, 2020
Ibrutinib for central nervous system lymphoma: the Australasian Lymphoma Alliance/MD Anderson Cancer Center experienceKatharine L Lewis, Collin K Chin, Kate Manos, et al.
European Journal of Haematology|July 3, 2024
A single-day polychemotherapy regimen with proteasome inhibitor combinations for relapsed/refractory myeloma in the era of novel therapiesEric Wenlong Li, Esther Jones, Christian Bryant, et al.
Pageof 2